Pulmonx (LUNG) Long-Term Debt Issuances (2020 - 2023)

Pulmonx (LUNG) reported Long-Term Debt Issuances of $20.0 million for Q1 2023, up 3695.07% quarter-over-quarter from $527000.0 in Q4 2020.

Pulmonx (LUNG) Long-Term Debt Issuances (2020 - 2023) Analysis & Trends

Pulmonx (LUNG) has 2 years of Long-Term Debt Issuances data on file, last reported at $20.0 million in Q1 2023.

Long-Term Debt Issuances for Q1 2023 came in at $20.0 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was $20.0 million (changed N/A YoY), and the FY2023 annual result was $20.0 million, changed N/A from the prior year.
Long-Term Debt Issuances grew to $20.0 million in Q1 2023 per LUNG's latest filing, from $527000.0 in the prior quarter.
Over five years, Long-Term Debt Issuances peaked at $20.0 million in Q1 2023 and troughed at -$32.5 million in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Abbott Laboratories	152.92 Bn	146.27 Bn	6.27 Bn	19.86 Bn
2	Stryker	119.50 Bn	116.62 Bn	3.81 Bn	-
3	Medtronic	102.71 Bn	94.54 Bn	5.76 Bn	-
4	Boston Scientific	69.72 Bn	68.51 Bn	3.61 Bn	-
5	Edwards Lifesciences	49.24 Bn	45.57 Bn	1.29 Bn	-
6	GE HealthCare Technologies	29.74 Bn	27.67 Bn	1.98 Bn	1.15 Bn
7	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	11.71 Mn
8	Dexcom	28.96 Bn	27.84 Bn	750.30 Mn	-
9	Steris	20.31 Bn	19.88 Bn	697.10 Mn	-
10	Pulmonx	58.34 Mn	-11.41 Mn	-	-

Download Data